Overexpression of IGF2BP3 As a Potential Oncogene in Ovarian Clear Cell Carcinoma

Liu, Huidi; Zeng, Zheng; Afsharpad, Mitra; Lin, Caiji; Wang, Siwen; Yang, Hao; Liu, Shuhong; Kelemen, Linda E.; Xu, Wenwen; Ma, Wenqing; Xiang, Qing; Mastriani, Emilio; Hwang, Pengfei; Wang, Jiali; Liu, Shulin; Johnston, Randal N.; Köbel, Martin

doi:10.2139/ssrn.3386275

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The experimented studies exhibited to be contrasted with the control group; the tumor size was considerably reduced after treatment with IGF2BP3siRNA. This also shows that IGF2BP3 has a cancer-promoting effect in OCCC [41]. In addition, the incidence of PAAD is closely related to changes in people's eating habits, smoking, heavy drinking, acute and chronic pancreatitis, type 2 diabetes, and stimulation by exposure to physical and chemical substances.…”

Section: Discussionmentioning

confidence: 70%

The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma

Zhang

2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. Pancreatic adenocarcinoma (PAAD) has become the major cause of cancer-related deaths globally. The m6A (N6-methyladenosine) alteration plays a crucial function in carcinogenesis and tumor progression. The role of genes related to m6A and their expression level in pancreatic cancer is not identified yet. The objective of this research analysis is a demonstration of the m6A RNA methylation regulators based as biomarkers for the PAAD diagnosis. Methods. About 23 extensively reported m6A RNA methylation regulators were identified through the Cancer Genome Atlas (TCGA) database. This identification was based on consensus clustering analysis, protein-protein integration (PPI) analysis, risk prognostic model, Cox-regression analysis, String Spearman analysis, and LASSO Cox-regression. Results. Herein, we conclude that 23 m6A methylation regulators have a strong link with the clinical and molecular characteristics of PAAD. The three subgroups (1/2) of pancreatic adenocarcinoma were identified using the clustering of 23 m6A regulators. Subgroup cluster 2 had a lower survival rate than the subgroup of cluster 1, and the difference in grades between the two groups was substantial. An assessment was performed using the 23 reported m6A methylation regulators. Eight of these can be used as independent PAAD prognostic markers. The consequences of variable IGF2BP3 expression in PAAD were then investigated further. Conclusions. The key finding of this study was that the m6A methylation regulator gene has the main role in pancreatic tumors, and it may be used as a biomarker in the prognosis of the PAAD and for therapy purposes.

show abstract

Section: Discussionmentioning

confidence: 70%

The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma

Zhang

2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Gene expression and sequencing studies created two similar broad clusters [ 89 ]. Individual poor prognostic markers are p53, CDKN2A and IGF2BP3 [ 90 , 91 ]. Nevertheless, candidate biomarkers did not predict differing responses to standard platinum-based chemotherapy [ 92 ], and the search for therapeutic targets is ongoing.…”

Section: Molecular Subtypes Of Ovarian Carcinomasmentioning

confidence: 99%

The Evolution of Ovarian Carcinoma Subclassification

Köbel

Kang

2022

Cancers

View full text Add to dashboard Cite

The phenotypically informed histotype classification remains the mainstay of ovarian carcinoma subclassification. Histotypes of ovarian epithelial neoplasms have evolved with each edition of the WHO Classification of Female Genital Tumours. The current fifth edition (2020) lists five principal histotypes: high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), mucinous carcinoma (MC), endometrioid carcinoma (EC) and clear cell carcinoma (CCC). Since histotypes arise from different cells of origin, cell lineage-specific diagnostic immunohistochemical markers and histotype-specific oncogenic alterations can confirm the morphological diagnosis. A four-marker immunohistochemical panel (WT1/p53/napsin A/PR) can distinguish the five principal histotypes with high accuracy, and additional immunohistochemical markers can be used depending on the diagnostic considerations. Histotypes are further stratified into molecular subtypes and assessed with predictive biomarker tests. HGSCs have recently been subclassified based on mechanisms of chromosomal instability, mRNA expression profiles or individual candidate biomarkers. ECs are composed of the same molecular subtypes (POLE-mutated/mismatch repair-deficient/no specific molecular profile/p53-abnormal) with the same prognostic stratification as their endometrial counterparts. Although methylation analyses and gene expression and sequencing showed at least two clusters, the molecular subtypes of CCCs remain largely elusive to date. Mutational and immunohistochemical data on LGSC have suggested five molecular subtypes with prognostic differences. While our understanding of the molecular composition of ovarian carcinomas has significantly advanced and continues to evolve, the need for treatment options suitable for these alterations is becoming more obvious. Further preclinical studies using histotype-defined and molecular subtype-characterized model systems are needed to expand the therapeutic spectrum for women diagnosed with ovarian carcinomas.

show abstract

“…Cao et al believed that the dysregulation of IGF2BP2 was related to insulin resistance, diabetes and carcinogenesis and may potentially become a powerful biomarker and candidate target for related diseases [24]. In fact, IGF2BP3 might differentiate normal tissues from cancerous tissues and serve as a prognostic marker for colorectal, hepatocellular, and ovarian clear-cell carcinomas [25][26][27]. Previous research has confirmed that IGF2BP3 is involved in cell growth and migration in early embryonic development [28].…”

mentioning

confidence: 99%

Expression and prognostic analyses of the insulin-like growth factor 2 mRNA binding protein family in human pancreatic cancer

Chen

Zhu

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background Despite advances in early diagnosis and treatment, cancer remains the leading cause of mortality worldwide. The insulin-like growth factor 2 mRNA binding protein (IGF2BP) family has been reported to be involved in a variety of human malignant tumours. However, little is known about their expression and prognostic value in human pancreatic cancer. Therefore, we performed a detailed cancer versus normal differential analysis. Methods The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) databases were used to analyse the mRNA expression levels of the IGF2BP family in various cancers, including pancreatic cancer. Then, the LinkedOmics and GEPIA databases were used to assess the relation between the expression levels of IGF2BPs and overall survival (OS). Then, univariate and multivariate Cox regression analyses were performed, and subgroups based on grade and stage were analysed. The signalling pathways associated with IGF2BP2 and IGF2BP3 were then investigated via gene set enrichment analysis (GSEA). Results IGF2BP2 and IGF2BP3 were associated with each subset of OS based on grade and stage. Further clinical correlation analysis of IGF2BP2 and IGF2BP3 confirmed that IGF2BP2 and IGF2BP3 are fundamental factors in promoting pancreatic cancer progression. Conclusion IGF2BP2 and IGF2BP3 are key factors in promoting the progression of pancreatic cancer and are closely related to overall survival.

show abstract

Overexpression of IGF2BP3 As a Potential Oncogene in Ovarian Clear Cell Carcinoma

Cited by 7 publications

References 0 publications

The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma

The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma

The Evolution of Ovarian Carcinoma Subclassification

Expression and prognostic analyses of the insulin-like growth factor 2 mRNA binding protein family in human pancreatic cancer

Contact Info

Product

Resources

About